News Tag: English

Bergen, Norway – 25 February 2021: Reference is made to the notice on 23 February 2021 and the Board of Directors approval of BerGenBio ASA’s (OSE:BGBIO) Annual Financial statement. The Annual Report for 2020 is available on the Company’s website: https://www.bergenbio.com/investors/  – END –  For further information, please contact:   Richard Godfrey, CEO, BerGenBio ASA +47 917 86 304  Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com +47 917 86 513  Forward looking statements   This announcement may contain forward-looking statements, … Read more

Bergen, Norway – 23 February 2021: The Board of Directors in BerGenBio ASA (the “Company”) (OSE:BGBIO) today approved the 2020 annual financial statements prepared in accordance with International Financial Reporting Standards (IFRS). The financial statements are in accordance with the preliminary 2020 annual financial statements published on 10 February 2021.   The annual report 2020 will be made available on BerGenBio ASA’s website www.bergenbio.com on 25 February 2021. … Read more

Bergen, Norway, 17 February 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for an oral virtual presentation at the annual Conference on Retroviruses and Opportunistic Infections (CROI 2021), taking place from 6-10 March 2021. The presentation will be given … Read more

Bergen, Norway, 10 February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the fourth quarter and full year 2020. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CET today, please see below … Read more

Bergen, Norway, 8[th ]February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, provides an update on the Company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India, following … Read more

Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory lung cancer  Bergen, Norway, 29 January 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will today present an update from its Phase II study of bemcentinib in combination with anti-PD-1 therapy pembrolizumab (BGBC008) in refractory non-small cell lung cancer (NSCLC) patients at an oral presentation at the 2020 World Conference on … Read more

Bergen, Norway, 27 January 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the fourth quarter 2020 on Wednesday 10 February 2021. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET.  The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will … Read more

· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory lung cancer Updated interim data will be presented on second line patients following CPI monotherapy Bergen, Norway, 13[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present … Read more

Bergen, Norway, 12[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a member of the senior management team is presenting at the following virtual conferences: Solebury Trout Management Access Event, 6-15 January 2021 Register for the event here (https://troutaccess.com/investor.php/contact/mailcheck/hash/566554ad12a903f0f24683765aa9ed77) … Read more

Bergen, Norway, 11[th] January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, provides an update on the Company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India, following … Read more

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close